|Bid||19.17 x 4000|
|Ask||19.80 x 1000|
|Day's Range||19.25 - 19.53|
|52 Week Range||12.43 - 20.93|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||24.03|
|Forward Dividend & Yield||0.83 (4.31%)|
|Ex-Dividend Date||Sep. 27, 2019|
|1y Target Est||20.90|
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy.
Takeda Receives Positive CHMP Opinion for Pre-filled Syringe Presentation of TAKHZYRO® (lanadelumab) for use as a Preventive Treatment for Hereditary
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) ("Takeda") today announces that on May 28, the European Commission (the "EC") has released Takeda from the obligation to divest the pipeline compound SHP647 and certain associated rights ("SHP647"), a commitment that was provided by Takeda to secure regulatory clearance of its acquisition of Shire plc ("Shire"). Takeda will discontinue the current SHP647 clinical trial program, and it will be providing all eligible trial participants with the opportunity to have continued access to SHP647 in a post-trial access ("PTA") study. In addition, subject to obtaining trial participant consents and the satisfaction of regulatory and ethical considerations, Takeda will make SHP647 clinical trial data and biosamples available to the scientific community through the Crohn’s & Colitis Foundation ("Foundation").
Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone.
Japan's Takeda Pharmaceutical Co Ltd <4502.T> will be allowed to keep a drug used to treat bowel disease because changes in the market have removed the need to sell it to allay EU antitrust concerns over last year's acquisition of Shire plc. Two years ago, the European Commission ordered the Japanese drugmaker to sell off the biologic drug SHP 647 developed by Shire to treat inflammatory bowel diseases. The EU competition enforcer said on Thursday it had reversed its decision after an investigation that followed Takeda's request to waive its pledge.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations.
Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) ("Takeda") today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29-31 and the 25th Virtual Congress of the European Hematology Association (EHA), June 11-14.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the European Commission (EC) extended the current conditional marketing authorization of ADCETRIS® (brentuximab vedotin) to include treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL), in combination with CHP (cyclophosphamide, doxorubicin, prednisone). Systemic anaplastic large cell lymphoma is a subtype of peripheral T-cell lymphoma (PTCL). The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on March 27, 2020.
Japan's machine tool orders in April fell to their lowest level in more than a decade, preliminary data showed on Thursday, in a sign the coronavirus pandemic is taking an deeper toll on the economy. Machine tool orders in April slumped 48.3% compared with a year earlier, a preliminary estimate from the Japan Machine Tool Builders' Association (JMTBA) showed. "Of course, there was a big decline, and it confirmed that companies are foregoing capital expenditure," said Atsushi Takeda, chief economist at Itochu Economic Research Institute.
Takeda Pharmaceutical Co Ltd could start a clinical trial as early as July for a potential treatment of COVID-19 that is based on antibodies from recovered patients' blood, company executives said on Wednesday. The clinical trial would include hundreds of patients and take several months to complete. "When the product will be available beyond the clinical study is still a bit unclear," Kim said on an investor call.
Takeda Pharmaceutical Co <4502.T> booked a surprise operating profit and forecast that income would triple this business year as hefty acquisition costs related to last year's $59 billion Shire takeover recede. Takeda also said it could start clinical trials in July for its plasma-derived therapy for COVID-19, initially called TAK-888, according to plasma division President Julie Kim. Japan's largest drugmaker estimated 355 billion yen (2.70 billion pounds)in operating profit for the year to March.
Takeda Pharmaceutical Company Limited (TOKYO: 4502) (NYSE: TAK) ("Takeda") today announced financial results for the year ended March 31, 2020 (FY2019). As a top 10 global R&D-driven biopharmaceutical company, Takeda is demonstrating its innovation and values in its response to COVID-19 and in positioning itself for long-term success.
Ladies and gentlemen, thank you for standing by, and welcome to the first-quarter 2020 Codexis earnings conference call. This is Bruce Voss with LHA. Thank you all for participating in today's Codexis call to discuss first-quarter 2020 financial results and recent business progress.
Approval makes Entyvio the only maintenance therapy approved across Europe with both IV and SC formulation options for adult patients with UC or CD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its investigational drug mobocertinib (TAK-788) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. There are currently no approved therapies designed to treat this specific form of NSCLC. Mobocertinib is a small-molecule tyrosine kinase inhibitor (TKI) designed to selectively target EGFR and human EGFR 2 (HER2) exon 20 insertion mutations.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it has entered into an agreement to divest a portfolio of select non-core over-the-counter (OTC) and prescription pharmaceutical products sold in Europe, and two manufacturing sites located in Denmark and Poland to Orifarm Group ("Orifarm"), a fast-growing Danish pharmaceutical company, for up to approximately $670 million USD subject to customary legal and regulatory closing conditions.
Johnson & Johnson <JNJ.N> said on Friday it abandoned plans to buy Takeda Pharmaceutical’s surgical patch product TachoSil, citing regulatory issues. Takeda <4502.T>, Japan’s biggest drugmaker, announced the sale of TachoSil, a surgical patch to control bleeding, to Johnson & Johnson's subsidiary Ethicon for $400 million last May. "Ethicon and Takeda have mutually decided to terminate the TachoSil transaction, agreeing that it was the right decision given the regulators’ concerns," a representative for Johnson & Johnson said in a statement.
Please replace the release with the following corrected version due to multiple revisions to the Octapharma boilerplate and inclusion of additional multimedia.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) extended the current marketing authorization of ALUNBRIG (brigatinib) to include use as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. This decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on February 27, 2020.
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) ("Takeda") today announced that its Board of Directors approved an executive compensation recoupment policy ("clawback policy"). The adoption of the clawback policy is part of Takeda’s ongoing efforts to further strengthen its commitment to best-in-class corporate governance and is consistent with Takeda’s industry peers.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion for the extension of the marketing authorization of ADCETRIS® (brentuximab vedotin) and recommended its approval in combination with CHP (cyclophosphamide, doxorubicin, prednisone) as a treatment for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). The positive CHMP opinion is based on the results of the Phase 3 ECHELON-2 study evaluating ADCETRIS in combination with CHP to a standard care, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), in previously untreated patients with CD30+ peripheral T-cell lymphoma (PTCL), including the subtype sALCL. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, which is expressed on the surface of several types of PTCL, including sALCL.
EU antitrust regulators have opened a full investigation into Johnson & Johnson's acquisition of Takeda Pharmaceutical's surgical patch product TachoSil, concerned that the deal could lead to reduced choice and higher prices for customers. Takeda, <4502.T> Japan's biggest drugmaker, announced the sale of TachoSil, a surgical patch for bleeding control, to U.S. giant Johnson & Johnson's <JNJ.N> subsidiary Ethicon for $400 million (342 million pounds) last May. The European Commission said a preliminary investigation found cause for concern because TachoSil is the market leader in Europe.